Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

The team spent 14 months investigating and found that the FDA had allowed more than 150 potentially unsafe drugs in the U.S.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

"A majority of commissions for the five most populous counties in the state," including Douglas, "recently fell short of ...

BERLIN ― Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products such as breast cancer drug Kisqali during the second quarter.

CNN chief data analyst Harry Enten on Wednesday pointed to new polling from the network that he said will serve as a stark ...

This week's question: Velvet Sundown, an AI-generated band that plays generic '70s country rock, is now racking more than 1 million listeners a month on Spotify. If the group were to release a rock ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

A woman is dead after being hit by a motorcycle on Cane Run Road, police say.According to LMPD, they were called to a crash ...

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to an 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and ...